Genenta Science S p A : Effectiveness of the Amended and Restated OSR License Agreement - Form 6-K

Effectiveness of the Amended and Restated OSR License Agreement


As previously disclosed in the Annual Report on Form 20-F for the fiscal year ended December 31, 2022 of Genenta... | May 1, 2023

Related Keywords

Italy ,United States ,Italian , ,Glaxosmithkline Intellectual Property Development ,Annual Report ,Law Decree ,Solid Cancer Indication ,Lympho Hematopoietic Indication ,Hematopoietic Indication ,Solid Cancer ,Genenta Sciences Pa Stock Exchange ,News ,Information ,Press Release ,Effectiveness ,F ,The ,Amended ,End ,Gestated ,Sr ,License ,Us ,Reviously ,Isclosed ,N ,Nnual ,Report ,Form ,Or ,Iscal ,Ear ,Nded ,December ,022 ,F Gnta Us36870w1009 ,